Health Care & Life Sciences » Pharmaceuticals | Ritter Pharmaceuticals Inc.

Ritter Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
448.20
2,747.20
15,819.60
7,046.30
22,632.00
14,801
Other Current Assets
76.60
57.10
189.10
156.80
167.40
421.50
Total Current Assets
524.90
2,804.40
16,008.70
7,203.00
22,799.40
15,277
Net Property, Plant & Equipment
7.50
5.20
20.70
23.50
23.90
20.20
Other Assets
15.40
153.80
10.30
10.30
10.30
22.70
Total Assets
547.70
2,963.30
16,039.70
7,236.90
22,833.60
15,319.90
ST Debt & Current Portion LT Debt
31.50
-
-
-
-
Other Current Liabilities
866.50
1,254.80
1,354.70
3,133.80
2,707.60
Total Current Liabilities
898.00
1,254.80
1,354.70
3,133.80
2,707.60
Total Liabilities
898.00
1,254.80
1,354.70
3,133.80
2,707.60
Common Equity (Total)
12,773.00
14,503.90
14,685.00
4,103.10
14,997.40
Total Shareholders' Equity
350.30
1,708.60
14,685.00
4,103.10
20,126.00
Total Equity
350.30
1,708.60
14,685.00
4,103.10
20,126.00
Liabilities & Shareholders' Equity
547.70
2,963.30
16,039.70
7,236.90
22,833.60
Preferred Stock (Carrying Value)
12,422.80
16,212.50
-
-
5,128.50

About Ritter Pharmaceuticals

View Profile
Address
1880 Century Park East
Los Angeles California 90067
United States
Employees -
Website http://www.ritterpharmaceuticals.com
Updated 07/08/2019
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J.